Cargando…

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies. METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Der Steen, Nele, Deben, Christophe, Deschoolmeester, Vanessa, Wouters, An, Lardon, Filip, Rolfo, Christian, Germonpré, Paul, Giovannetti, Elisa, Peters, Godefridus J, Pauwels, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2016
Materias:	Basic Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143436/ https://www.ncbi.nlm.nih.gov/pubmed/28008383 http://dx.doi.org/10.5306/wjco.v7.i6.425

Ejemplares similares

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients
por: Deben, Christophe, et al.
Publicado: (2017)

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
por: Van Der Steen, Nele, et al.
Publicado: (2016)

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies
por: Van Der Steen, Nele, et al.
Publicado: (2019)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
por: Van Der Steen, Nele, et al.
Publicado: (2020)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
por: Deben, Christophe, et al.
Publicado: (2021)

Better to Be Alone than in Bad Company: Cognate Synonyms Impair Word Learning
por: Antón, Eneko, et al.
Publicado: (2020)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

Salt and sugar: Bad company
por: Wada, Jun
Publicado: (2016)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Better to Be in Bad Company than to Be Alone? Aedes Vectors Respond Differently to Breeding Site Quality in the Presence of Others
por: Riback, Thais I. S., et al.
Publicado: (2015)

Cellular senescence in cancer: clinical detection and prognostic implications
por: Domen, Andreas, et al.
Publicado: (2022)

Good Men in Bad Company—an Explanation Which Explains
por: Lydston, G. Frank
Publicado: (1905)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein
por: Wouters, An, et al.
Publicado: (2014)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays
por: Limame, Ridha, et al.
Publicado: (2012)

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
por: Boeckx, Carolien, et al.
Publicado: (2014)

Broken business: seven steps to reform good companies gone bad
por: Hernandez, José R, et al.
Publicado: (2018)

Chronic DREADD Isn’t As Bad As It Sounds
por: Hyder, Safwan K., et al.
Publicado: (2020)

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
por: Zaryouh, Hannah, et al.
Publicado: (2021)

Microglial Cells in Epilepsy: Not That Bad After All?
por: Jones, Nigel C.
Publicado: (2020)

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
por: Van Der Steen, Nele, et al.
Publicado: (2015)

In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells
por: Wouters, An, et al.
Publicado: (2010)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA
por: Hou, Xin-Fang, et al.
Publicado: (2017)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Bad company: Loneliness longitudinally predicts the symptom cluster of pain, fatigue, and depression in older adults
por: Powell, Victoria D., et al.
Publicado: (2022)

Better to be in agreement than in bad company: A critical analysis of many kappa-like tests
por: Silveira, Paulo Sergio Panse, et al.
Publicado: (2022)

The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines
por: Pauwels, Bea, et al.
Publicado: (2006)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer
por: Harmon, Tia, et al.
Publicado: (2017)

Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
por: Baay, Marc, et al.
Publicado: (2011)

Calcium antagonists modulate oxidative stress and acrosomal reaction in rat spermatozoa
por: Morakinyo, Ayodele, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nriegsmhmprtb4mb79vncochgh